New Phase 3b data on Lilly's Taltz and Zepbound used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Lilly's Jaypirca recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy
